专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009137080A1 COMPOSITIONS OF GNRH RELATED COMPOUNDS AND PROCESSES OF PREPARATION 审中-公开
标题翻译： GNRH相关化合物的组合物和制备方法
公开(公告)号：WO2009137080A1
公开(公告)日：2009-11-12
申请号：PCT/US2009/002844
申请日：2009-05-07
申请人： MERRION RESEARCH III LIMITED , LEE, Amanda , ADAMCZYK, Bozena , COUGHLAN, David, C. , O'TOOLE, Edel , LEONARD, Thomas, W.
发明人： LEE, Amanda , ADAMCZYK, Bozena , COUGHLAN, David, C. , O'TOOLE, Edel , LEONARD, Thomas, W.
IPC分类号： A61K38/09 , A61K47/06 , A61P5/24
CPC分类号： A61K38/09 , A61K9/2846 , A61K9/4891 , A61K47/12 , A61K47/14 , C07K7/06
摘要： The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling characteristics of the composition are a factor. The compositions of the present invention comprise a therapeutically effective amount of one or more GnRH related compound, and a sufficient amount of at least one anti-gelling agents to reduce the gelation of the GnRH related compound. The present invention also provides processes for preparation of a composition of one or more GnRH related compound, wherein the process comprises mixing the GnRH related compound with one or more anti-gelling agents, wherein the anti-gelling agent comprises a medium chain fatty acid salt, or an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent.
摘要翻译：本发明提供了适合于口服给药，可注射给药和其它形式给药的GnRH相关化合物的组合物，其中组合物的胶凝特性是一个因素。本发明的组合物包含治疗有效量的一种或多种GnRH相关化合物和足够量的至少一种抗凝胶剂以减少GnRH相关化合物的凝胶化。本发明还提供一种制备一种或多种GnRH相关化合物的组合物的方法，其中该方法包括将GnRH相关化合物与一种或多种抗凝胶剂混合，其中抗凝胶剂包括中链脂肪酸盐，或中链脂肪酸的酯，醚或衍生物，并且具有约4-约20个碳原子的碳链长度，或者是表面活性剂。

2. 发明申请

WO2007146234A3 SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER 审中-公开
标题翻译：固体口服剂量增强剂
公开(公告)号：WO2007146234A3
公开(公告)日：2008-02-28
申请号：PCT/US2007013693
申请日：2007-06-11
申请人： MERRION RES II LTD , LEONARD THOMAS W , O'TOOLE EDEL , FEENEY ORLAGH
发明人： LEONARD THOMAS W , O'TOOLE EDEL , FEENEY ORLAGH
IPC分类号： A61K38/00 , A61K38/12
CPC分类号： A61K31/165 , A61K9/2013 , A61K9/2077 , A61K9/2846 , A61K31/19 , A61K31/403 , A61K38/12
摘要： The invention relates to a pharmaceutical composition and oral dosage forms comprising a DAC inhibitor in combination with an enhancer to promote absorption of the DAC inhibitor at the GIT cell lining. The enhancer can be a medium chain fatty acid or derivative thereof having a carbon chain length of from 6 to 20 carbon atoms. In certain embodiments, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.
摘要翻译：本发明涉及药物组合物和口服剂型，其包含DAC抑制剂与增强剂的组合，以促进DAC抑制剂在GIT细胞衬里的吸收。增强剂可以是碳链长为6至20个碳原子的中链脂肪酸或其衍生物。在某些实施方案中，固体口服剂型是缓释剂型，例如延迟释放剂型。

3. 发明申请

WO2007117706A2 SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER 审中-公开
标题翻译：固体口服剂型包含增强剂
公开(公告)号：WO2007117706A2
公开(公告)日：2007-10-18
申请号：PCT/US2007/008935
申请日：2007-04-09
申请人： MERRION RESEARCH II LIMITED , LEONARD, Thomas W.
发明人： LEONARD, Thomas W.
IPC分类号： A61K31/675 , A61K31/663
CPC分类号： A61K31/19 , A61K9/0053 , A61K9/1617 , A61K9/1635 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2846 , A61K31/20 , A61K31/663 , A61K31/675 , A61K47/12 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.
摘要翻译：本发明涉及药物组合物和口服剂型，其包含双膦酸盐与增强剂的组合，以增强双膦酸盐向底层循环的肠输送。优选地，增强剂是碳链长度为6至20个碳原子的中链脂肪酸或中链脂肪酸衍生物，并且固体口服剂型是缓释剂型，例如延迟释放剂型。

4. 发明申请

WO2007115106A2 OCUUPANCY SENSOR POWERBASE 审中-公开
标题翻译： OCUUPANCY传感器电源
公开(公告)号：WO2007115106A2
公开(公告)日：2007-10-11
申请号：PCT/US2007/065523
申请日：2007-03-29
申请人： LEVITON MANUFACTURING CO., INC. , LEONARD, Thomas, W. , LEINEN, Richard, A. , ENGEL, John, B.
发明人： LEONARD, Thomas, W. , LEINEN, Richard, A. , ENGEL, John, B.
IPC分类号： B01F3/04
CPC分类号： G08B19/00
摘要： The present invention discloses an apparatus and method for converting a low voltage occupancy sensor to a powered stand-alone unit. The invention uses a low voltage occupancy sensor mounted in an upper portion of a housing with its associated low voltage wiring terminating in a terminal block. An attachable corresponding lower housing is provided with a power pack adapted to connect with the low voltage terminal block wherein once combined the upper and lower housing portions combine to form an integral powered stand-alone sensor unit.
摘要翻译：本发明公开了一种将低电压占用传感器转换为动力独立单元的装置和方法。本发明使用安装在外壳的上部的低电压占用传感器，其相关联的低电压布线终止在端子块中。一个可连接的相应的下壳体设置有适于与低压端子块连接的电源组件，其中一旦组合了上壳体部分和下壳体部分组合以形成一体的动力独立的传感器单元。

5. 发明申请

WO2004045580A3 METHODS OF PROVIDING CONTROLLED-RELEASE PHARMACEUTICAL COMPOSITIONS AND CONTROLLED-RELEASE PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：提供控制释放药物组合物和控制释放药物组合物的方法
公开(公告)号：WO2004045580A3
公开(公告)日：2004-09-10
申请号：PCT/US0337130
申请日：2003-11-19
申请人： BARR LAB INC , LEONARD THOMAS W , PONDER GARRATT W , HOLSHOUSER CHRISTOPHER L
发明人： LEONARD THOMAS W , PONDER GARRATT W , HOLSHOUSER CHRISTOPHER L
IPC分类号： A61K9/20 , A61K9/22 , A61K9/28
CPC分类号： A61K9/2866 , A61K9/2054 , A61K9/2095
摘要： Methods are disclosed for forming a solid pharmaceutical composition having a desired release profile that include selecting hydroxypropylmethyl cellulose having a particular particle distribution to obtain the desired release profile, and forming a solid pharmaceutical composition comprising a core that comprises a bio-active and the hydroxypropylmethyl cellulose. Solid pharmaceutical compositions are also disclosed that include a bio-active, and hydroxypropylmethyl cellulose having a particle size that is selected to obtain a desired release profile.
摘要翻译：公开了用于形成具有所需释放曲线的固体药物组合物的方法，其包括选择具有特定颗粒分布的羟丙基甲基纤维素以获得所需的释放曲线，以及形成包含芯的固体药物组合物，其包含生物活性物质和羟丙基甲基纤维素。还公开了包含生物活性的羟丙基甲基纤维素和具有选择以获得所需释放曲线的粒度的羟丙基甲基纤维素的固体药物组合物。

6. 发明申请

WO2003057855A2 SYNTHESIS OF A MIXTURE OF SULFATED ESTROGENS USING A SULFUR TRIOXIDE COMPLEX 审中-公开
标题翻译：使用三硫化钼复合物的硫酸化雌激素混合物的合成
公开(公告)号：WO2003057855A2
公开(公告)日：2003-07-17
申请号：PCT/US2003/000275
申请日：2003-01-07
申请人： ENDEAVOR PHARMACEUTICALS , LEONARD, Thomas, W.
发明人： LEONARD, Thomas, W.
IPC分类号： C12N
CPC分类号： C07J1/00 , C07J31/006
摘要： A process of producing a stable composition comprising a mixture of sulfated estrogens. The mixture of sulfated estrogens may comprise sulfated alkali metal salts of Δ 8,9 -dehydroestrone, estrone, and derivatives thereof or other estrogens. The process comprises the steps of sulfating such mixture of alkali metal salts of Δ 8,9 -dehydroestrone, estrone, and derivatives thereof with a sulfur trioxide complex and adding tris(hydroxymethyl)aminomethane.
摘要翻译：一种生产包含硫酸化雌激素混合物的稳定组合物的方法。硫酸化雌激素的混合物可以包含DELTA8,9-脱氢雌酮，雌酮及其衍生物或其它雌激素的硫酸化碱金属盐。该方法包括以下步骤：将这些DELTA8,9-脱水雌酮碱金属盐，雌酮及其衍生物的混合物与三氧化硫络合物硫酸化并加入三（羟甲基）氨基甲烷。

7. 发明申请

WO2002095352A2 PATIENT COMPLIANCE AND MONITORING SYSTEM 审中-公开
标题翻译：患者遵守和监测系统
公开(公告)号：WO2002095352A2
公开(公告)日：2002-11-28
申请号：PCT/US2002/015117
申请日：2002-05-15
申请人： ENDEAVOR PHARMACEUTICALS, INCORPORATED , WALDON, R., Forrest , LEONARD, Thomas, W.
发明人： WALDON, R., Forrest , LEONARD, Thomas, W.
IPC分类号： G01N
CPC分类号： G06Q50/22 , G06F19/00 , G06F19/3456 , G06F19/3481 , G16H10/20
摘要： This invention is directed to methods and systems for monitoring compliance with or effectiveness of hormone replacement therapy. The methods and systems of the invention provide an efficient means of communication between medical professionals and patients for between visit monitoring of patient compliance with a prescribed hormone therapy and the effectiveness of the treatment recommended.
摘要翻译：本发明涉及用于监测激素替代疗法的依从性或有效性的方法和系统。本发明的方法和系统提供医疗专业人员和患者之间的有效的沟通方式，用于在对患者遵守规定的激素治疗之间进行访视监测和推荐治疗的有效性之间。

8. 发明申请

WO2009137078A1 COMPOSITIONS OF PEPTIDES AND PROCESSES OF PREPARATION THEREOF 审中-公开
标题翻译：肽的组合物及其制备方法
公开(公告)号：WO2009137078A1
公开(公告)日：2009-11-12
申请号：PCT/US2009/002842
申请日：2009-05-07
申请人： MERRION RESEARCH III LIMITED , LEONARD, Thomas, W.
发明人： LEONARD, Thomas, W.
IPC分类号： A61K38/09 , A61K47/06
CPC分类号： A61K38/09 , A61K9/2846 , A61K9/4891 , A61K47/12 , A61K47/14 , C07K7/06
摘要： The present invention provides composition of comprising a therapeutically effective amount of at least one peptide, polypeptide, analog or derivative thereof and a sufficient amount of at least one stabilizing agent to improve the stability of the peptide, polypeptide, an analog or derivative thereof, wherein at least one stabilizing agent is a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent. The method for preparation of a composition of a peptide, polypeptide, protein, an analog and/or derivative thereof is also provided. The process comprises mixing the peptide, polypeptide, protein, an analog or derivative thereof with a sufficient amount of at least one stabilizing agents to improve the stability of the peptide, polypeptide, protein, an analog or derivative thereof, and the agent is a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent.
摘要翻译：本发明提供包含治疗有效量的至少一种肽，多肽，类似物或衍生物和足够量的至少一种稳定剂以提高肽，多肽，其类似物或衍生物的稳定性的组合物，其中至少一种稳定剂是中链脂肪酸盐，酯，醚或中链脂肪酸的衍生物，并且具有约4至约20个碳原子的碳链长度或者是表面活性剂。还提供了制备肽，多肽，蛋白质，其类似物和/或衍生物的组合物的方法。该方法包括将肽，多肽，蛋白质，其类似物或衍生物与足够量的至少一种稳定剂混合以改善肽，多肽，蛋白质，其类似物或衍生物的稳定性，并且该药剂是培养基链脂肪酸盐，酯，醚或中链脂肪酸的衍生物，并且具有约4至约20个碳原子的碳链长度或者是表面活性剂。

9. 发明申请

WO02092102A3 TREATMENT OF CONDITIONS RELATING TO HORMONE DEFICIENCIES BY ADMINISTRATION OF PROGESTINS 审中-公开
标题翻译：通过行政管理处理有关恶魔缺陷的条件
公开(公告)号：WO02092102A3
公开(公告)日：2003-03-20
申请号：PCT/US0215690
申请日：2002-05-16
申请人： ENDEAVOR PHARMACEUTICALS , LEONARD THOMAS W
发明人： LEONARD THOMAS W
IPC分类号： A61K31/566 , A61K31/569 , A61K31/57 , A61K45/06 , A61P15/12 , A61K31/565
CPC分类号： A61K45/06 , A61K31/566 , A61K31/569 , A61K31/57 , A61K2300/00
摘要： The present invention includes methods for preventing endometrial hyperplasia associated with estrogen therapy through the administration of a progestin agent. The methods presented may include starting the administration of a progestin agent at a high dose, and then lowering the dose.
摘要翻译：本发明包括通过施用孕激素剂预防与雌激素治疗相关的子宫内膜增生的方法。所给出的方法可以包括以高剂量开始给予孕激素，然后降低剂量。

10. 发明申请

WO02058706A3 COMBINATION OF AN ESTROGEN AND AN ANDROGEN FOR TREATING HORMONAL DEFICIENCIES IN WOMEN UNDERGOING ESTROGEN REPLACEMENT THERAPY 审中-公开
标题翻译：雌激素与雌雄同体化合物治疗雌激素替代治疗妇女的非霍奇金属缺乏症
公开(公告)号：WO02058706A3
公开(公告)日：2003-03-13
申请号：PCT/US0151045
申请日：2001-12-21
申请人： ENDEAVOR PHARMACEUTICALS , LEONARD THOMAS W , WALDON R FORREST
发明人： LEONARD THOMAS W , WALDON R FORREST
IPC分类号： A61K31/56 , A61K31/565 , A61K31/566 , A61K31/567 , A61K31/568 , A61K31/57 , A61K31/58 , A61K31/585 , A61P5/24 , A61P5/30 , A61P9/00 , A61P15/00 , A61P15/12 , A61P19/10 , A61P25/28 , A61P43/00
CPC分类号： A61K31/56 , A61K31/565 , A61K31/568 , A61K2300/00
摘要： The present invention combines the administration of estrogens with the administration of non-aromatizing androgens to treat hormonal deficiencies in women undergoing estrogen replacement therapy.
摘要翻译：本发明结合了雌激素的施用与非芳香化雄激素的施用以治疗进行雌激素替代疗法的妇女的激素缺乏。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式